<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904055</url>
  </required_header>
  <id_info>
    <org_study_id>218066</org_study_id>
    <nct_id>NCT04904055</nct_id>
  </id_info>
  <brief_title>Evaluating the Impact of a Value-based Prescription Drug Formulary</brief_title>
  <acronym>VBF-e</acronym>
  <official_title>Value-based Formulary-Essentials: Testing and Expanding on Value in Prescription Drug Benefit Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Donaghue Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the impact of the value-based formulary on patient&#xD;
      out-of-pocket spending and health plan spending as well as the impact of the value-based&#xD;
      formulary on medication use, emergency department visits, hospitalizations, and outpatient&#xD;
      office visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total spending for prescription drugs</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on patient out-of-pocket plus health plan spending on prescription drugs per member per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient out-of-pocket spending for prescription drugs</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on patient out-of-pocket spending for prescription drugs per member per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health plan spending for prescription drugs</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on health plan spending for prescription drugs per member per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total healthcare spending</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on total healthcare spending per member per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency department visits</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on number of emergency department visits per member per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in hospital</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on number of days in hospital per member per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of outpatient office visits</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on number of outpatient office visits per member per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days supply of medication</measure>
    <time_frame>From 24 months before insurance transition until up to 36 months after transition</time_frame>
    <description>Impact of value-based formulary on days supply of medication per member per month</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">36333</enrollment>
  <condition>Value-Based Health Insurance</condition>
  <arm_group>
    <arm_group_label>Value-based Formulary Beneficiaries</arm_group_label>
    <description>enrolled in the value-based formulary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Formulary Beneficiaries</arm_group_label>
    <description>enrolled in a standard (i.e., non-value-based formulary)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Value-based Formulary</intervention_name>
    <description>Prescription drug formulary tiers informed by estimated value</description>
    <arm_group_label>Value-based Formulary Beneficiaries</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All individuals who satisfy the eligibility criteria are included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals:&#xD;
&#xD;
               -  aged 0-64&#xD;
&#xD;
               -  Continuously enrolled in an employer-sponsored health plan for at least 12 months&#xD;
                  (with one-month allowable gap) prior to the index date&#xD;
&#xD;
                    -  For individuals in the exposed group, the index date is defined as the start&#xD;
                       date of value-based formulary implementation at the employer group level&#xD;
&#xD;
                    -  For individuals in the control group, the index date is defined as the index&#xD;
                       date of the matched exposed individual&#xD;
&#xD;
          -  Employer groups:&#xD;
&#xD;
               -  that transition to the value-based formulary if they transitioned all enrollees&#xD;
                  in that employer group (no individual selection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Individuals with:&#xD;
&#xD;
          -  missing gender information&#xD;
&#xD;
          -  missing zip code level demographics at all member months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Yeung, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cost Sharing / economics</keyword>
  <keyword>Formularies as Topic</keyword>
  <keyword>Insurance, Health / economics</keyword>
  <keyword>Value-Based Health Insurance / economics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be made available per data use agreement.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT04904055/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

